Skandinaviska Enskilda Banken AB publ Purchases 111,668 Shares of AnaptysBio, Inc. $ANAB

Skandinaviska Enskilda Banken AB publ grew its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 333.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 145,191 shares of the biotechnology company’s stock after acquiring an additional 111,668 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in AnaptysBio were worth $4,446,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ANAB. Bessemer Group Inc. boosted its position in shares of AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the period. Osaic Holdings Inc. lifted its stake in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 2,326 shares during the period. Profund Advisors LLC bought a new position in shares of AnaptysBio during the 3rd quarter worth approximately $201,000. Finally, Covestor Ltd grew its position in shares of AnaptysBio by 131,540.0% during the 3rd quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock worth $201,000 after buying an additional 6,577 shares during the period.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, Director Magda Marquet sold 11,000 shares of AnaptysBio stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $48.23, for a total transaction of $530,530.00. Following the completion of the transaction, the director owned 9,930 shares in the company, valued at approximately $478,923.90. The trade was a 52.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric J. Loumeau sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $44.86, for a total value of $560,750.00. Following the sale, the insider directly owned 9,088 shares of the company’s stock, valued at $407,687.68. This represents a 57.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 156,280 shares of company stock valued at $7,254,939 over the last three months. Corporate insiders own 33.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Wall Street Zen cut shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Wells Fargo & Company lifted their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. HC Wainwright dropped their price objective on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Monday, November 24th. Finally, Stifel Nicolaus reduced their target price on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $66.89.

AnaptysBio Trading Down 2.3%

Shares of ANAB stock opened at $54.19 on Friday. The firm has a fifty day simple moving average of $48.80 and a two-hundred day simple moving average of $36.61. AnaptysBio, Inc. has a 12 month low of $13.99 and a 12 month high of $57.65. The firm has a market capitalization of $1.50 billion, a PE ratio of -19.22 and a beta of 0.35.

AnaptysBio declared that its Board of Directors has initiated a stock buyback plan on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.